



(51) International Patent Classification:

C07D 263/48 (2006.01) A61P 37/06 (2006.01)
A61K 31/421 (2006.01) A61P 37/08 (2006.01)
A61P 37/00 (2006.01)

(21) International Application Number:

PCT/EP2013/068198

(22) International Filing Date:

3 September 2013 (03.09.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant: SAREUM LIMITED [GB/GB]; Unit 2A,
Langford Arch, London Road, Pampisford, Cambridge-
shire CB22 3FX (GB).

(72) Inventor: READER, John Charles; Unit 2A, Langford
Arch, London Road, Pampisford, Cambridgeshire CB22
3FX (GB).

(74) Agent: SCHLICH; 9 St Catherine's Road, Littlehampton,
West Sussex BN17 5HS (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: PHARMACEUTICAL COMPOUNDS



(57) Abstract: The invention provides a compound which is an amide of the formula (2): or a salt or stereoisomer thereof; wherein: R⁷ is selected from chlorine and fluorine; R³, R⁴, R⁵ and R⁶ are each independently selected from hydrogen, fluorine and chlorine; n is 0, 1 or 2; Q¹ is selected from C(=O), S(=O) and SO₂; A is absent or is NR²; R¹ is selected from: - hydrogen; - an optionally substituted C₁₋₆ non-aromatic hydrocarbon group; and - 3- to 7-membered non-aromatic carbocyclic and heterocyclic rings containing one or two heteroatom ring members selected from O, N and S, and bridged bicyclic heterocyclic rings of seven to nine ring members of which one or two are nitrogen atoms, the carbocyclic and heterocyclic rings and bridged bicyclic heterocyclic rings being optionally substituted; R² is selected from hydrogen and C₁₋₄ alkyl; or NR¹R² forms an optionally substituted 4- to 7-membered non-aromatic nitrogen-containing heterocyclic ring optionally containing a second heteroatom ring member selected from nitrogen and oxygen; with the provisos that: (i) no more than two of R³ to R⁶ are other than hydrogen; and (ii) when R⁷ and R⁶ are both fluorine, then one of R³ to R⁵ is chlorine or fluorine and/or R¹-A-Q¹ is selected from ethylsulfonyl and isopropylsulfonyl. Also provided are pharmaceutical compositions containing the compounds and their therapeutic uses.

